ASX Announcements


 
    Change of Director's Interest - Philip Powell  
 
    IIQ Investor Presentation  
 
    Change of Director's Interest - Dr Geoffrey Cumming  
 
    Change of Director's Interest - Philip Powell  
 
    INOVIQ Investor Briefing Invitation  
 
    Australian Patent Granted for SubB2M Technology  
 
    INOVIQ Key Manufacturing Agreement to Advance SubB2M tests  
 
    IIQ Appendix 4C & Quarterly Activities Report - March 2022  
 
    INOVIQ CSO Co-Authors Scientific Statement on Exosomes  
 
    Notification of cessation of securities - IIQ  
 
    Updated Investor Presentation  
 
    SubB2M Paper Published in BMC Cancer Journal  
 
    INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests  
 
    INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test  
 
    Update on Legal Proceedings and BARD1 Autoantibody Program  
 
    Appendix 4D and Half Year Financial Report  
 
    Brazilian Patent Issued for Lung & Colorectal Cancer  
 
    Notification regarding unquoted securities - IIQ  
 
    Appendix 4C & Quarterly Activities Report  
 
    US Patent Issued - BARD1 Breast & Ovarian Cancer Diagnosis  
 
    INOVIQ Awarded Additional BTB Funding to Develop SubB2M test  
 
    INOVIQ Appendix 4G and Corporate Governance Statement  
 
    Chinese Patent Issued in BARD1 Patent Family for Lung Cancer  
 
    Appendix 3Y - Change of Director's Interest Notice x 4  
 
    Notification regarding unquoted securities - IIQ  
 
    BARD1 Changes its Name to INOVIQ  
 
    Cleansing Notice - Issue of Four Shares - Resolution 5 AGM  
 
    Application for quotation of securities - BD1  
 
    Application for quotation of securities - BD1  
 
    Results of 2021 Annual General Meeting  
 
    AGM Presentation  
 
    New BARD1 Exosome Liquid Biopsy Project  
 
    Application for quotation of securities - BD1  
 
    Notification regarding unquoted securities - BD1  
 
    US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis  
 
    EXO-NET ANZSEV Presentation  
 
    BARD1 Presenting at Bell Potter Healthcare Conference  
 
    EXO-NET Presented at Virtual ANZSEV Symposium  
 
    Jobkeeper Payment Notification  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Ceasing to be a substantial holder  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4C & Quarterly Activities Report  
 
    Change of Director's Interest - Philip Powell  
 
    Amended Remuneration Table Directors Report  
 
    Notice required under listing rule 3.13.1  
 
    Notification of cessation of securities - BD1  
 
    2021 Annual Report  
 
    BARD1 Appoints New CSO  
 
    Notification of cessation of securities - BD1  
 
    Appendix 4E and Preliminary Financial Report  
 
    Change in substantial holding  
 
    Change of Director's Interest - Powell  
 
    Change of Director's Interest - Dr Geoffrey Cumming  
 
    Change of Director's Interest - Johnston  
 
    Notification of cessation of securities - BD1  
 
    Appendix 2A  
 
    BARD1 Share Purchase Plan Completed Oversubscribed  
 
    Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test  
 
    BARD1 LODGES SPP AND OPTIONS PROSPECTUS  
 
    Appendix 4C & Quarterly Activities Report  
 
    Appendix 2A  
 
    BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data  
 
    Updated Investor Presentation  
 
    Terms of issue of Options  
 
    Investor Presentation  
 
    Appendix 3B  
 
    BARD1 $15m Placement to Accelerate Cancer Diagnostic Program  
 
    Trading Halt  
 
    BARD1 Investor Presentation  
 
    BARD1 Autoantibody Test Results for Ovarian Cancer Published  
 
    SubB2M Breast Cancer Test Manuscript Submitted  
 
    Update on Legal Proceedings  
 
    R&D Tax Incentive Refund Received  
 
    BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test  
 
    BARD1 Files Two New Patents Protecting SubB2M & EXO-NET  
 
    BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference  
 
    BARD1 Launches its RUO EXO-NET Product  
 
    Appendix 4C and Quarterly Activities Report  
 
    Positive Results from the BARD1 Autoantibody Assay  
 
    Appendix 3G - Long Term Incentive Options Issued to CEO  
 
    BARD1 Signs Option Agreement for Type 3C Diabetes Test  
 
    Appendix 2A  
 
    Positive Results Evaluation of EXO-NET in Pancreatic Cancer  
 
    Appendix 2A  
 
    Australian Patent Granted for hTERT  
 
    BARD1 Achieves hTERT Registration and First Order in Korea  
 
    Appendix 2A  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder  
 
    Appendix 4D and Half-year financial report  
 
    Commencement of Legal Proceedings Against BARD1  
 
    Appendix 2A  
 
    Ceasing to be a substantial holder  
 
    Becoming a substantial holder  
 
    Excellent SubB2M Breast Cancer Test Data  
 
    Outstanding SubB2M Ovarian Cancer Test Data  
 
    Change of Auditor  
 
    Appendix 4C & Quarterly Activities Report  
 
    U.S. Patent Granted for NET Technology for Exosome Capture  
 
    Final Director's Interest Notice - Dr Irminger-Finger  
 
    Dr Irminger steps down from Board, continues as Consultant  
 
    Change of Director's Interest Notice - Cumming  
 
    Change of Director's Interest Notice - Powell  
 
    Change of Director's Interest Notice - Johnston  
 
    Final Director's Interest Notice - Helen Fisher  
 
    Patent Granted in China for hTERT  
 
    Further Detail on BARD1's US Sales Strategy  
 
    Trading Halt  
 
    Pause in Trading  
 
    Results of Meeting  
 
    AGM & CEO Presentations and Chairman's Transcript  
 
    Consolidation/Split - BD1  
 
    Helen Fisher Steps Down from BARD1 Board  
 
    BARD1 Gains New High-volume Customer for its hTERT Test  
 
    Appendix 4C and Quarterly Activities Report  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Notice of AGM ASX Listing Rule 3.13.1  
 
    Successful BARD1 Kit Evaluation  
 
    BARD1 Awarded BTB Funding to Develop Breast Cancer Test  
 
    Revised Securities Trading Policy  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and Annual Report to Shareholders  
 
    Change of Director's Interest - Helen Fisher  
 
    Change of Director's Interest - Dr Geoffrey Cumming  
 
    European Patent Validated  
 
    Change in substantial holding  
 
    Initial Director's Interest Notice - Fisher  
 
    Initial Director's Interest Notice - Cumming  
 
    Change of Director's Interest Notice - Powell  
 
    Change of Director's Interest Notice - Johnston  
 
    Final Directors Interest - Gunzburg  
 
    Change in substantial holding  
 
    Quarterly Business Update & Appendix 4C  
 
    Appendix 2A - Issue of Scheme Shares  
 
    BARD1 COMPLETES SIENNA ACQUISITION  
 
    SDX: Implementation of Scheme of Arrangement  
 
    Appointment of Chief Scientific Officer  
 
    Quarterly Activities Report & Appendix 4C  
 
    Receipt of R&D Tax Incentive Refund  
 
    BARD1 Signs Contract with Griffith University  
 
    Half Yearly Report and Accounts  
 
    Appendix 4C Quarterly Cashflow Report  
 
    Appendix 3Y - Cripps  
 
    Director Appointment  
 
    Details of Company Address  
 
    Appendix 3B  
 
    Appendix 3Y - Irminger-Finger  
 
    Constitution  
 
    Results of Meeting  
 
    AGM Presentation  
 
    Appendix 4C - quarterly  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 3Y - Irminger-Finger  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Phase 3 Assay Development Milestone Reached  
 
    Appendix 3B  
 
    Long Term Incentives for CEO  
 
    Appendix 3Y - Irminger-Finger  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4E and Annual Report to Shareholders  
 
    Quarterly Business Update and Appendix 4C  
 
    Change in Substantial Shareholding - Irminger-Finger  
 
    Appendix 3Y - Powell  
 
    Appendix 3Y - Johnston  
 
    Appendix 3Y - Irminger-Finger  
 
    Appendix 3Y - Gunzburg  
 
    Completion of Capital Raising Package  
 
    Appendix 3B and Cleansing Notice 708A  
 
    Closure of Entitlement Offer and Shortfall Notification  
 
    Progress on Assay Development Program  
 
    Despatch of Offer Document  
 
    603 SSN - Merchant Funds Management Pty Ltd  
 
    603 SSN - Jeffrey Emmanuel  
 
    603 Initial SSN - Moggs Creek Pty Ltd ATF Moggs Creek S/F  
 
    Letters to Shareholders  
 
    Appendix 3X - Powell  
 
    Appendix 3X - Johnston  
 
    Appendix 3Z - Montgomery  
 
    Letter to Optionholders  
 
    Cleansing Notice Section 708(AA)  
 
    Cleansing Notice Section 708(A)  
 
    Offer Document  
 
    Appendix 3B  
 
    Capital Raising and Board Changes  
 
    Trading Halt  
 
    EUROPEAN PATENT VALIDATED  
 
    R&D Tax Incentive Refund  
 
    U.S. Patent Issued  
 
    Appendix 4C - quarterly  
 
    Response to ASX Price and Volume Query  
 
    Half Yearly Report and Accounts  
 
    Cancer Vaccine Study Results  
 
    Quarterly Business Update and Appendix 4C  
 
    Change in Substantial Holding  
 
    Change of Directors Interest - Irminger-Finger  
 
    Change of Directors Interest - Montgomery  
 
    Change of Directors Interest - Gunzburg  
 
    Shortfall Confirmation and Appendix 3B  
 
    Closure of Entitlement Offer and Shortfall  
 
    Change of Director's Interest Notice  
 
    Results of Meeting  
 
    AGM Presentation  
 
    Despatch of Offer Document  
 
    Letters to Shareholders  
 
    Appendix 3B  
 
    Cleansing Notice Rights Issue  
 
    Rights Offer Document  
 
    Company Presentation  
 
    Appendix 3B  
 
    Capital Raising Indicative Timetable  
 
    Non-Renounceable Issue  
 
    Trading Halt  
 
    Pause In Trading  
 
    Ceasing to be a substantial holder  
 
    Quarterly Activities Report and Cashflow  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Grant of Additional Chinese Patent Core BARD1 Patent Family  
 
    Development of world first BARD1 Breast Cancer Test  
 
    Appendix 4G  
 
    Annual Report to Shareholders  
 
    Investor Presentation and Update  
 
    Ceasing to be a substantial holder  
 
    Bard1 Ovarian Test Results  
 
    Appendix 4E  
 
    Final Director's Interest Notice  
 
    Death of Non-Executive Director  
 
    Quarterly Activities Report and Appendix 4C  
 
    US Patent Issued Protecting BARD1 Ovarian Test  
 
    Appendix 3B Release of Securities from Escrow  
 
    Improved Performance of BARD1 Ovarian Test  
 
    Notice under ASX Listing Rule 3.10A  
 
    Reinstatement to Official Quotation  
 
    Response to ASX Price Query  
 
    Contract Development Agreement Signed  
 
    Voluntary Suspension  
 
    Trading Halt  
 
    Quarterly Business Update and Appendix 4C  
 
    Becoming a substantial holder  
 
    Appendix 3B and Cleansing Statement  
 
    Corporate Presentation  
 
    Capital Raising  
 
    Israeli Patent Issued in Bard1 Core Patent Family  
 
    Trading Halt  
 
    Additional BARD1 Ovarian Test Results  
 
    Half Yearly Report and Accounts  
 
    Appendix 3B (Advisor Options)  
 
    Grant of Japanese Patent  
 
    Quarterly Business Update and Appendix 4C  
 
    RESULTS OF BARD1 OVARIAN CANCER STUDY  
 
    Results of Meeting  
 
    AGM Presentation  
 
    Quarterly Business Update and Appendix 4C  
 
    Notice of Annual General Meeting  
 
    Research and Development Update  
 
    Appendix 4G  
 
    Annual Report to Shareholders  
 
    Appendix 4E Preliminary Financial Results  
 
    Publication of BARD1 Lung Cancer Test  
 
    Appendix 3B  
 
    Australian Patent Issued  
 
    Completion of Share Purchase Plan  
 
    Quarterly Activities Report & Appendix 4C  
 
    Appointment of Dr Samuel Janes  
 
    Completion of Capital Raising  
 
    Appendix 3B and Cleansing Notice  
 
    Share Purchase Plan Cleansing Statement  
 
    Share Purchase Plan Document  
 
    Capital Raising  
 
    Trading Halt  
 
    Shareholder Update  
 
    Lung Cancer Study Results  
 
    Quarterly Activities Report and Appendix 4C  
 
    Shareholder Update  
 
    Cancer Vaccine Collaboration  
 
    Appendix 3B  
 
    OVARIAN CANCER CLINICAL STUDY RESULTS  
 
    GRANT OF U.S. PATENT  
 
    Appendix 4D and Half Yearly Reports and Accounts  
 
    Successful Assay Feasibility Results  
 
    Quarterly Activities Review and Appendix 4C  
 
    CEO Terms of Employment  
 
    AGM RESULTS  
 
    AGM PRESENTATION  
 
    Appointment of CEO  
 
    Quarterly Activities Report and Appendix 4C  
 
    Appendix 4G  
 
    Annual Report to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Statutory Audited Financial Statements  
 
    Company Update - Promising Result for Ovarian Cancer  
 
    Preliminary Final Report - Appendix 4E  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Quarterly Activities Report and Appendix 4C  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Becoming a Substantial Holder - Walker  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3Y - Gunzburg  
 
    Becoming a substantial holder  
 
    Confirmations to ASX  
 
    Terms of Securities  
 
    Confirmation in relation to restricted securities  
 
    Securities Trading Policy  
 
    Use of Funds Information  
 
    Pro-forma Statement of Financial Position  
 
    BARD1AG Financial Statements 2015  
 
    BARD1AG Financial Statements 2014  
 
    BARD1AG Financial Statements 2013  
 
    Constitution  
 
    Appendix 1A and Information Form & Checklist  
 
    Capital Structure  
 
    Top 20 Shareholders  
 
    Distribution Schedule  
 
    Pre-reinstatement Disclosure  
 
    ASX Notice  
 
    Reinstatement to Official Quotation - 20 June 2016  
 
    Appendix 3Z - Collinson  
 
    Appendix 3X - Laurent  
 
    Appendix 3X - Irminger  
 
    Appendix 3Y - Gunzburg  
 
    Appendix 3B  
 
    Receipt of Signed Restriction Agreement  
 
    Extension to deadline for automatic removal  
 
    Capital Raising Closed Oversubscribed  
 
    Quarterly Activities Report and App 5B  
 
    Replacement Prospectus  
 
    Results of Meeting  
 
    PROSPECTUS  
 
    Notice of General Meeting  
 
    Quarterly Activities Report and Appendix 5B  
 
    Half Year Accounts